A review of the use of indirect treatment comparisons to support Health Technology Assessments in Ireland
Previous PostThe experience and utilisation of patient reported outcomes (PROs) in Leber's hereditary optic neuropathy (LHON): A targeted literature review
Next PostAssessing the definition and outcomes of innovative drugs by Health Technology Assessment bodies in England, France, and Italy (Q1 2023)